Morphine Market Overview
The Morphine Market Size was valued at USD 20.03 billion in 2023 and is projected to reach USD 32.81 billion by 2032, expanding at a CAGR of 5.66% during the forecast period of 2024 to 2032. Morphine remains a cornerstone for pain management in numerous medical disciplines, including oncology, orthopedic care, and post-operative recovery, especially among the aging global population.
Get a Sample Report of Morphine Market @
https://www.snsinsider.com/sample-request/2597
Morphine Market Drivers
Growing Burden of Chronic Pain and Geriatric Diseases
A rising geriatric population and the global increase in chronic pain conditions such as arthritis, cancer, and musculoskeletal disorders are primary growth drivers. According to the CDC and WHO, over 1.7 billion people suffer from musculoskeletal conditions, and nearly 50% of those over 65 are impacted by arthritis—making effective pain management solutions like morphine indispensable.
Technological Advancements in Drug Delivery
New drug delivery systems, including sustained-release transdermal patches, are improving the efficacy, safety, and adherence associated with morphine therapy. Innovations minimize side effects while offering prolonged pain relief, particularly for chronic pain sufferers. These developments enhance the drug’s clinical value and encourage broader adoption across health systems.
Supportive Government Policies in Developing Markets
Increased acceptance of opioids for medical use in emerging economies, combined with growing healthcare investments and relaxed regulatory frameworks, are unlocking new avenues for market expansion. Governments in countries like India and China are promoting legitimate access to pain medications, boosting market penetration in previously under-served regions.
Morphine Market Segmentation
By Dosage Form
Injectables dominated the market in 2023, holding nearly 70% share due to rapid onset of action, making them the go-to choice in hospitals and acute care settings.
Oral formulations are the fastest-growing segment, driven by rising outpatient prescriptions, ease of administration, and increased patient compliance for long-term pain management.
By Application
Pain management remains the dominant application with nearly 80% share in 2023, primarily for use in postoperative care, palliative care, and cancer pain.
The cold and cough suppressant segment is expected to witness rapid growth through 2032. Morphine’s efficacy in managing severe cough associated with respiratory infections is gaining traction in integrated clinical practices.
Regional Outlook
North America
Accounted for 45.8% of global market share in 2023.
Driven by established pharmaceutical infrastructure, robust opioid demand in palliative care, and consistent investments in pain therapy research.
The U.S. leads the region due to extensive hospital usage, while Canada shows strong growth on the back of policy changes favoring broader morphine access.
Asia-Pacific
Poised to be the fastest-growing region from 2024 to 2032.
Growth driven by increased prevalence of chronic diseases, greater awareness of pain treatment, and enhanced accessibility to morphine.
China and India lead the regional growth with large populations and improved medical infrastructure enabling wider morphine adoption.
For A Detailed Briefing Session with Our Team of Analysts, Connect with Us Now@
https://www.snsinsider.com/request-analyst/2597
Key Companies in the Morphine Market
Major Drug Manufacturers
Purdue Pharma
Daiichi Sankyo Inc.
Taj Pharmaceuticals Limited
Sanofi Winthrop Industries
Mallinckrodt Pharmaceuticals
Mayne Pharma Group Limited
Sun Pharmaceutical Industries
Leading Raw Morphine Suppliers
Manus Aktteva Biopharma LLP
Macfarlan Smith
Qinghai Pharmaceutical
Northeast Pharmaceutical Group
Alcaliber
Verve Health Care Ltd.
Johnson Matthey Fine Chemicals
Pfizer Inc.
Read Our Related Report:
Recent Developments
August 2024: The FDA approved Zurnai (nalmefene injection) auto-injector for emergency opioid overdose reversal, signaling growing regulatory attention on opioid safety alongside pain management needs.
May 2024: Purdue Pharma L.P. launched a program to deliver low-cost opioid use disorder (OUD) treatments in correctional facilities, aligning with public health goals and addressing opioid-related challenges
Conclusion
As the global burden of chronic pain escalates, the morphine market is set for consistent growth backed by clinical necessity, geriatric expansion, and pharmaceutical innovation. With injectable formats dominating the landscape and oral therapies on the rise, the future of morphine lies in balanced, regulated, and technologically enhanced applications that ensure both efficacy and safety. Emerging markets, in particular, offer lucrative growth potential as access, awareness, and government support continue to improve.
About US
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company’s aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.
Contact Us:
Jagney Dave – Vice President of Client Engagement
Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK)
Email: [email protected]
